Eikon Therapeutics, Inc. Common Stock
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs using a platform that permits precise characterization of protein interactions in living cells. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor respons… Read more
Eikon Therapeutics, Inc. Common Stock (EIKN) - Total Assets
Latest total assets as of September 2025: $649.03 Million USD
Based on the latest financial reports, Eikon Therapeutics, Inc. Common Stock (EIKN) holds total assets worth $649.03 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Eikon Therapeutics, Inc. Common Stock - Total Assets Trend (2023–2024)
This chart illustrates how Eikon Therapeutics, Inc. Common Stock’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Eikon Therapeutics, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
Eikon Therapeutics, Inc. Common Stock's total assets of $649.03 Million consist of 46.4% current assets and 53.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 26.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2023–2024)
This chart illustrates how Eikon Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eikon Therapeutics, Inc. Common Stock's current assets represent 46.4% of total assets in 2024, a decrease from 83.0% in 2023.
- Cash Position: Cash and equivalents constituted 26.3% of total assets in 2024, up from 21.5% in 2023.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2023.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Eikon Therapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of Eikon Therapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Eikon Therapeutics, Inc. Common Stock - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Eikon Therapeutics, Inc. Common Stock generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Eikon Therapeutics, Inc. Common Stock is currently not profitable relative to its asset base.
Eikon Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.69 | 4.04 | - |
| Quick Ratio | 8.69 | 4.04 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | $345.56 Million | $ 171.44 Million | - |
Eikon Therapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Eikon Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -6.6% |
| Total Assets | $491.24 Million |
| Market Capitalization | $109.14K USD |
Valuation Analysis
Below Book Valuation: The market values Eikon Therapeutics, Inc. Common Stock's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Eikon Therapeutics, Inc. Common Stock's assets decreased by 6.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Eikon Therapeutics, Inc. Common Stock (2023–2024)
The table below shows the annual total assets of Eikon Therapeutics, Inc. Common Stock from 2023 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $491.24 Million | -6.56% |
| 2023-12-31 | $525.71 Million | -- |